- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01870505
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Women age ≥ 18 years
- Willing and able to comply with scheduled visits, treatment plan and laboratory tests
- Willing and able to consent for biopsy of locally-advanced or metastatic breast cancer prior to treatment
- Metastatic or locally-advanced unresectable breast cancer (includes metastatic or locally-advanced unresectable breast cancer which is diagnosed while on adjuvant letrozole or exemestane)
- Histologically documented HR+ breast cancer in either the primary or metastatic setting, as defined by ER or PR ≥ 1%; results from the local lab are acceptable. Eligibility will not be affected by HER2 status.
- The most recent treatment prior to enrollment must be one of the following (duration of treatment ≥2 weeks), and must have been adequately tolerated according the treating physician's judgment:
- Letrozole
- Exemestane
- Exemestane + everolimus (everolimus must be discontinued for ≥ 3 weeks prior to starting study treatment)
- Letrozole or exemestane in combination with an experimental agent(s) on a clinical trial, provided that the experimental agent(s) is not a PI3K inhibitor or AKT inhibitor (experimental agent(s) must be discontinued for ≥ 3 weeks prior to starting study treatment)
- Any number of prior endocrine therapies (including tamoxifen, fulvestrant and/or aromatase inhibitors in either the adjuvant or metastatic setting) and any number of prior chemotherapy regimens. Anti-cancer systemic therapy, such as chemotherapy or biologics or endocrine therapy, other than the AI, must be discontinued for ≥ 3 weeks prior to starting study treatment.
- For the dose-finding phase, patients must also have stable disease OR progression of disease on the most recent treatment. For the expansion phase, patients must have progression of disease on the most recent treatment. Progression of disease is defined as new or worsening disease on objective imaging. Progression of disease includes recurrence diagnosed while on adjuvant letrozole or exemestane.
- Postmenopausal women, as defined by one of the following (estradiol assay cutoff takes into account that the patient is on aromatase inhibitor therapy):
- Age ≥ 55 years and one year or more of amenorrhea
- Age < 55 years and one year or more of amenorrhea, with an estradiol assay within the post-menopausal range
- Age < 55 years with prior hysterectomy but intact ovaries, with an estradiol assay within the post-menopausal range
- Surgical menopause with bilateral oophorectomy
- Ovarian suppression with a LH-RH agonist, with an estradiol assay within the post-menopausal range at baseline and periodically on-study Measurable or non-measurable disease per RECIST criteria v1.1
- ECOG performance status 0-1
- Adequate organ function, as defined by all of the following:
Hematologic parameters:
- Absolute neutrophil count (ANC) ≥ 1500/μl (without growth factor support)
- Platelets ≥ 100,000/μl (no transfusion allowed within 2 weeks)
- Hemoglobin ≥ 9.0 g/dl (may be reached by transfusion)
- Liver function:
- Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) unless attributable to Gilbert's syndrome
- AST ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present
- ALT ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present
Kidney function:
- Creatinine ≤ 1.5 ULN
- Endocrine function:
- Fasting plasma glucose <140 mg/dl (may be on antiglycemic agents other than insulin). Fasting glucose measurement must be obtained at least 8 hours after the most recent caloric intake.
- Ability to swallow oral medication
- Willing to discontinue all herbal preparations / medications at least 7 days prior to the first dose of study drug and throughout the study. These include, but not limited to,St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.
Exclusion Criteria:
- Pregnant patients or women who are breast-feeding (patients must be postmenopausal, see Section 6.1.9)
Patients with central nervous system (CNS) involvement may participate if:
- Clinically stable with respect to the CNS tumor at the time of screening and >4 weeks from prior therapy completion (including radiation and/or surgery) to the start of study treatment
- Not receiving steroid therapy
- Not receiving enzyme inducing anti-epileptic medications that were started for brain metastases (these include carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate, and vigabatrin) Prior PI3K inhibitor or AKT inhibitor (patients previously treated with everolimus are eligible, see rationale in Section 3.6)
- History of toxicity to the most recent AI (letrozole or exemestane) that warrants cessation of the AI
- Patients who have received radiotherapy ≤ 2 weeks prior to starting study treatment
- Patients who have undergone major surgery ≤ 4 weeks prior to starting study treatment, who have not recovered from side effects of such procedure
- Uncontrolled diabetes (as defined by fasting glucose ≥ 140mg/dL) and/or insulin-dependent diabetes. Fasting glucose measurement must be obtained at least 8 hours after the most recent caloric intake. Patients currently requiring the use of antiglycemic agents (other than insulin) may be enrolled if fasting glucose <140mg/dL.
- Current need for chronic corticosteroid therapy (≥10mg of prednisone daily or an equivalent dose of other corticosteroid), or patients who have received systemic corticosteroids ≤ 2 weeks prior to starting study drug
- Current therapeutic anticoagulation with warfarin (or coumarin derivatives) Active infection or serious underlying medical condition that would impair the patient's ability to receive protocol treatment
- Clinically significant cardiac disease or impaired cardiac function, such as:
- Congestive heart failure requiring treatment (e.g., New York Heart Association Class II, III or IV) Acute coronary syndromes < 3 months prior to screening (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting)
- Uncontrolled arterial hypertension defined by blood pressure > 140/100 mm Hg at rest (average of 3 consecutive readings)
- History or current evidence of unstable, clinically significant cardiac arrhythmias or patients that require medications with a narrow therapeutic window, atrial fibrillation and/or conduction abnormality, e.g. congenital long QT syndrome, high-Grade/complete AV-blockage
- Corrected QT interval (QTc) > 480 msec on screening ECG Patients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment (see Section 9.6.3 and Appendix F)
- Impaired gastrointestinal function or poorly controlled gastrointestinal disease that may significantly alter the absorption of oral BYL719 (e.g. Crohn's disease, ulcerative colitis, malabsorption syndrome, small bowel resection, uncontrolled nausea or vomiting, or grade ≥ 3 diarrhea of any etiology) based on treating physician assessment
- Patients may not have a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Arm A: BYL719 plus Letrozole
For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added.
A treatment cycle will consist of 28 days.
Treatment doses for each AI will be fixed at the established dose.
Patients will continue on treatment until progression of disease or unacceptable toxicity.
The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
|
|
Sperimentale: Arm B: BYL719 plus Exemestane
For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added.
A treatment cycle will consist of 28 days.
Treatment doses for each AI will be fixed at the established dose.
Patients will continue on treatment until progression of disease or unacceptable toxicity.
The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
|
|
Sperimentale: Arm C: BYL719 plus Letrozole
For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle.
The starting dose of BYL719 in Arms C will be 250mg daily.
Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
|
|
Sperimentale: Arm D: BYL719 plus Exemestane
For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.
Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle.
For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study.
Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
phase II dose of BYL719 (Arm A and Arm B)
Lasso di tempo: 2 years
|
Three patients will be enrolled onto Cohort 0 at the starting BYL719 dose of 300mg daily.
All patients within a cohort will be observed for toxicity for one cycle (28 days) prior to entering additional patients.
|
2 years
|
phase II dose of BYL719 (Arm C and Arm D)
Lasso di tempo: 2 years
|
For Arms C and D, the starting dose of BYL719 for the first cohort (Cohort 0) will be 250mg daily.when
administered in combination with letrozole in a 1 week on, 1 week off schedule, or with exemestane in a 5 of 7 days weekly schedule, to patients with HR+ locally-advanced or metastatic breast cancer
|
2 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
safety and tolerability of BYL719 (Arm A, B, C and D)
Lasso di tempo: 2 years
|
Toxicity will be tabulated using the NCI Common Toxicity Criteria (CTCAE), version 4.0.
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the study medication, meeting any of the criteria listed in the table below, and occurring during Cycle 1 (≤ 28 days following the first dose of BYL719, including those in which the event started in Cycle 1 and the confirmation of the DLT occurs in a subsequent cycle).
|
2 years
|
efficacy of BYL719 (Arm A and Arm B)
Lasso di tempo: 2 years
|
Progression-free survival
|
2 years
|
efficacy of BYL719 (Arm C and Arm D)
Lasso di tempo: 2 years
|
in two distinct schedules, plus letrozole or exemestane, in patients with HR+ locally-advanced or metastatic breast cancer, by calculation of the following in an expansion cohort:. Progression-free survival
|
2 years
|
evaluate mechanisms of acquired resistance (Arms A, B, C and D)
Lasso di tempo: 2 years
|
with correlative studies of on-treatment and optional post-progression tumor biopsies
|
2 years
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Sarat Chandarlapaty, MD, PhD, Memorial Sloan Kettering Cancer Center
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie della pelle
- Neoplasie
- Neoplasie per sede
- Malattie del seno
- Neoplasie mammarie
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Ormoni, sostituti ormonali e antagonisti ormonali
- Antagonisti ormonali
- Inibitori dell'aromatasi
- Inibitori della sintesi di steroidi
- Antagonisti degli estrogeni
- Letrozolo
- Exemestane
Altri numeri di identificazione dello studio
- 13-027
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su BYL719
-
Columbia UniversityCompletato
-
Novartis PharmaceuticalsCompletatoTumore solido avanzatoGiappone
-
Novartis PharmaceuticalsA disposizioneSpettro di crescita eccessiva relativo a PIK3CA (PROS)
-
Lawson Health Research InstituteAttivo, non reclutanteTumore a cellule squamose della testa e del colloCanada
-
Peter MacCallum Cancer Centre, AustraliaNovartis PharmaceuticalsCompletatoCancro al seno metastaticoAustralia
-
Yonsei UniversitySconosciutoCarcinoma a cellule squamose ricorrente o metastatico della testa e del colloCorea, Repubblica di
-
Novartis PharmaceuticalsAttivo, non reclutanteSpettro di crescita eccessiva relativo a PIK3CA (PROS)Spagna, Francia, Irlanda, Stati Uniti
-
New Mexico Cancer Care AllianceNon più disponibile
-
Novartis PharmaceuticalsCompletatoMieloma multiplo recidivato e refrattarioItalia, Germania, Singapore, Australia, Stati Uniti
-
Array BioPharmaCompletatoUno studio di fase Ib su MEK162 più BYL719 in pazienti adulti con tumori solidi avanzati selezionatiAntiriciclaggio | Tumori solidi avanzati e selezionati | MDS ad alto rischio e ad altissimo rischioStati Uniti, Australia, Italia, Spagna, Francia, Svizzera, Regno Unito